Holen Sie sich die Stockscreener-App
27.51
0.51%
0.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$27.37
Offen:
$27.53
24-Stunden-Volumen:
6.50M
Relative Volume:
1.61
Marktkapitalisierung:
$14.12B
Einnahmen:
$11.89B
Nettoeinkommen (Verlust:
$-560.00M
KGV:
-25.01
EPS:
-1.1
Netto-Cashflow:
$191.00M
1W Leistung:
-2.62%
1M Leistung:
-8.27%
6M Leistung:
-13.57%
1J Leistung:
-22.20%
1-Tages-Spanne:
$27.36
$28.18
1-Wochen-Bereich:
$27.36
$28.48
52-Wochen-Spanne:
$26.25
$40.49
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
27.51 | 14.50B | 11.89B | -560.00M | 191.00M | -1.10 |
|
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter - Business Wire
Baxter International Inc. Stock Analysis and ForecastTremendous financial leverage - Autocar Professional
Cullen Frost Bankers Inc. Raises Position in Baxter International Inc. (NYSE:BAX) - MarketBeat
Is Baxter International Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
Richard Pzena's Strategic Acquisition of Baxter International Inc. Shares - GuruFocus
Cooke & Bieler LP Reduces Position in Baxter International Inc. (NYSE:BAX) - MarketBeat
What analysts say about Baxter International Inc. stockFree High-Return Strategy Alerts - Autocar Professional
What drives Baxter International Inc. stock priceExceptional risk-adjusted gains - Autocar Professional
Baxter International Q2 2025 Financial Results Conference Call - AInvest
New York State Common Retirement Fund Has $21.34 Million Stock Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Invests $8.43 Million in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter: Margin-Focused Model Faces Growth Constraints (NYSE:BAX) - Seeking Alpha
How Renae Kezar will Lead Sustainability at Baxter - Healthcare Digital
Healthcare: Who is Renae Kezar, Baxter’s New CSO? - Sustainability Magazine
Further weakness as Baxter International (NYSE:BAX) drops 6.1% this week, taking five-year losses to 65% - simplywall.st
Baxter International (NYSE:BAX) Price Target Cut to $27.00 by Analysts at Morgan Stanley - MarketBeat
Baxter to Host Second-Quarter 2025 Financial Results Conference Call for Investors - Business Wire
Baxter International Inc. (NYSE:BAX) to Issue Quarterly Dividend of $0.17 - MarketBeat
Baxter International's Upcoming Q2 2025 Earnings AnnouncementNews and Statistics - IndexBox
What To Expect From Baxter International's Q2 2025 Earnings Report - Barchart.com
Baxter appoints Andrew Hider as CEO - MSN
Baxter Intl: Analyst Sentiments and 12-Month Price Targets - AInvest
Assessing Baxter Intl: Insights From 5 Financial Analysts - Benzinga
Morgan Stanley Trims Baxter International Price Target to $27 From $28, Maintains Underweight Rating - MarketScreener
Baxter price target lowered to $27 from $28 at Morgan Stanley - TipRanks
Baxter International's Dividend Policy: A Steady Beacon in a Shifting Medtech Landscape - AInvest
Baxter International Keeps Quarterly Dividend at $0.17 a Share, Payable Oct. 1 to Shareholders of Record Aug. 29 - MarketScreener
Baxter Declares Quarterly Dividend - Business Wire
Citigroup Cuts Baxter International (NYSE:BAX) Price Target to $32.00 - MarketBeat
Medical Equipment Maker Baxter International Names New CEO - MSN
UBS Affirms Neutral Rating on Baxter International (BAX) - MSN
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
ARGA Investment Management LP Grows Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Evercore ISI Cuts Baxter International (NYSE:BAX) Price Target to $42.00 - MarketBeat
Analysts Set Baxter International Inc. (NYSE:BAX) PT at $36.14 - MarketBeat
Citigroup Adjusts Baxter International's Price Target to $32 From $34, Keeps Neutral Rating - MarketScreener
Baxter International (BAX) Receives a Hold from Wells Fargo - The Globe and Mail
Transformed Baxter, in search of stability after changes, turns to outsider CEO - Crain's Chicago Business
Baxter International Appoints Andrew Hider as New CEO - The Globe and Mail
Baxter International looking to bounce back - MarketScreener
Non-PVC IV Bags Market Is Booming So Rapidly 2025-2032 -Baxter - openPR.com
Baxter International Inc. stock underperforms Monday when compared to competitors - MSN
Baxter International's New Leadership: Can Andrew Hider Steer the Medtech Giant to Sustainable Growth? - AInvest
Baxter International taps Andrew Hider as CEO - Reuters
Baxter International appoints new CEO, months after former leader abruptly retired - Chicago Tribune
Baxter International drops after co names new CEO - TradingView
Baxter names Andrew Hider as next CEO - Medical Economics
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):